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ABSTRACT 
RUNX proteins, master regulators of development, are 
frequently dysregulated in cancers, particularly leukaemia and 
breast cancer. A common drug for RUNX cancers, Paclitaxel, 
is derived from the bark of the Taxus plant. We tested 
compounds derived from leaves and needles of Taxus as a 
sustainable source of compounds to treat RUNX cancers. We 
accessed the effectiveness of Paclitaxel, Cephalomannine and 
10-Deacetylbacatin III (10-DAB), in a Caenorhabditis 
elegans RUNX cancer model. Our results show Taxol 
derivatives have nuanced potency, affect development and 
fertility as well as reduce hyperproliferation. This research 
paves the way for further C. elegans based research using 
Taxol compounds against RUNX.  
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Introduction 
Cancer-related mortality is considered a leading cause of 
death, with 8.8 million deaths in 20151. The family of Runt-
related transcription factors, RUNX, are master regulators of 
various developmental pathways2 and are often described as 
possessing both an oncogenic and tumour suppressive 
function3,4. Mutations in  all mammalian RUNX genes have 
been shown to result in various cancers including breast, 
prostate, intestinal, lung and epithelial cancers3, as well as 
acute lymphoblastic leukaemia and acute myeloid leukaemia5. 
Therefore, developing drugs that specifically target RUNX 
may prove effective against a wide variety of cancers5,6.  
 
A novel family of drugs, the Taxanes, have proven to be 
effective in the treatment of RUNX cancers7,8. One, Paclitaxel, 
functions by binding and stabilising ß-tubulin, ultimately 
resulting in cell cycle arrest9. Studies with human 
osteosarcoma cell lines (Saos-2) show the mechanism of 
action of Paclitaxel is to inhibit microtubule-associated 
shuttling of RUNX between the nucleus and cytoplasm7. 
Paclitaxel is a natural product found in the bark of the Taxus 
plant which is commonly grown in the Netherlands. However, 
extraction of Paclitaxel is detrimental for the plant as well as 
being economically costly. Consequently, the supply of 
Paclitaxel is limited and this has prompted efforts to identify 
renewable sources of Paclitaxel. Cephalomannine and 10-
Deacetylbaccatin III (10-DAB) are two derivatives of 
Paclitaxel which are found in the needles and twigs of the 
Taxus plant, these could potentially provide a sustainable and 
economically viable source of a cancer drug. However, 
Cephalomannine and 10-DAB have not yet been evaluated for 
their anti-cancer potency. Thus, the aim of this study is to 
evaluate the effectiveness of Paclitaxel and its derivatives to 
treat RUNX related cancer using a Caenorhabditis elegans 
model system.  
 
C. elegans is a unique platform to study the effects of 
Paclitaxel as the nematode has conserved disease pathways 
and genetic compatibility to mammals11,12. Indeed, the 1mm 
long nematode has a single RUNX homolog, rnt-1, that is 
required for proliferation in the stem cell-like seam cells6. 
Adult C. elegans have 16 neuroectodermal seam cells on each 
side of the animal (Figure 1A)13,14. In contrast, a nematode that 
lacks rnt-1 shows a reduced number of seam cell nuclei 
(Figure 1B), whereas overexpression of rnt-1 and/or bro-1 
causes hyperproliferation of seam cells, which is effectively 
seen as being tumour-like6 (Figure 1C). C. elegans provides 
an opportunity to investigate drugs (and other compounds) in 
a simple whole-organism system that lacks RUNX gene 
redundancy and is amenable to the 3Rs (the Reduction, 
Replacement and Refinement of animal testing models). 
 
Figure 1: Representative image of worms that carry the seam cell 
marker. (A) Wild type L4 stage C. elegans showing the nuclei of 16 seam 
cells. The strain is JR667 and carries an integrated GFP reporter in every seam 
cell. (B) rnt-1 mutant, strain AW187, which has 10 seam cells per side. (C) 
rnt-1 bro-1 over-expressing strain, AW257, that carries an integrated rnt-
1::gfp and bro-1::gfp reporter. This strain has more seam cells per side, a 
tumour-like phenotype. All scale bars are 100µm.  
 
The aim of this study is to evaluate the effectiveness of 
Paclitaxel and its derivatives to treat RUNX related cancer, 
using a C. elegans RUNX model system. Firstly, the toxicity 
of the Taxol derivatives are explored using the standard 
outputs of development and brood size (fertility). Then, we 
evaluate the effects of Taxol derivatives on the number of stem 
cell-like seam cells and its effects in our C. elegans rnt-1 
cancer model. 
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Materials and methods 
Worm maintenance: C. elegans strains were maintained on 
Nematode Growth Media (NGM) agar prepared according to 
standard protocols and plates seeded with OP50 E. coli as a 
bacterial food source13 and maintained at 20°C. The following 
strains were used: Wild-type Bristol N2 strain; JR667 (wIs51 
[SCMp::GFP+unc-119+]) the wild type animal carrying an 
integrated seam cell GFP reporter15; the rnt-1 mutant AW187 
(rnt-1(tm388)I;him-5(e1489)wIs51[SCMp::GFP+ 
unc119+]V); AW257(msIs114[rnt-1::GFP+rol-6];msIs344 
[bro-1::GFP]) the over-expressing strain with a tumour-like 
phenotype. 
Taxol and its derivatives: Taxol derivatives were acquired 
from the Avans Hogeschool and stored at either -80°C (solid) 
or -20°C (in solution). Taxol derivatives were added to the 
molten NGM media to the desired concentrations. 
Reproduction assays: To determine brood size, L4 larvae 
(n=10) were maintained individually under standard 
conditions16. At the onset of egg-laying, animals were 
transferred to a fresh plate daily until egg laying ceased (3-4 
days at 22oC). Progeny from each plate were counted and 
added together. 
Developmental assays: Developmental fitness was assed 
using the method described by Xiong et al17. L1 animals 
(n=24) were maintained individually under standard 
conditions and the number of animals in each developmental 
stage was noted every 12 hours for 3 days, until egg laying 
began. The concentrations used were 100µg/ml Paclitaxel, 
50µg/ml Cephalomannine and 250µg/ml of 10-DAB. 
Seam cell assays: Strains carrying the integrated seam cell 
specific GFP marker were used to observe seam cell number 
at the L4 stage15. To take images, worms were mounted onto 
2% agarose pads in 0.1% sodium azide. Fluorescent imaging 
was carried out using a Zeiss Imager. M2 microscope and 
photomicrographs were taken using a x40 objective (Zeiss) 
and Zeiss Zen 2012 Blue Software. Figures were compiled 
using R software package and the statistical analysis applied 
was a 2-tailed unpaired t-test.  
 
Results  
Developmental and reproductive toxicity (DART) assays 
were performed to evaluate a dose response to all 3 
compounds (Paclitaxel, Cephalomannine and 10-DAB). 
Control animals laid 276 viable offspring, a similar number to 
animals exposed to 0.2% DMSO (Figure 2). Exposure to the 
Taxol derivatives did not affect brood size at low 
concentrations (data not shown). When C. elegans were 
exposed to the Taxol derivatives at concentrations of 
100µg/ml for Paclitaxel, 50µg/ml Cephalomannine and 
250µg/ml 10-DAB, the result was a significant reduction in 
the number of viable offspring compared to the control 
(respective cumulative brood size is 79, 68 and 78, p<0.001). 
 
A developmental fitness assay was performed to investigate 
the effects of Paclitaxel and its derivatives on the rate of larval 
development. The fitness assay showed the percentage of 
worms within a specific larval stage of development, every 12 
hours (Figure 3, hours 12 and 60 not shown).  
Figure 2: DART assay results from exposed Taxol derivatives. Graph 
indicating cumulative number of offspring (n=10). Wild type animals lay 276 
and 275 viable offspring under control and DMSO vehicle conditions 
respectively (dark grey bars). Exposure to Paclitaxel (Pac), Cephalomannine 
(Ceph) and 10-DAB significantly reduced cumulative brood size (light grey 
bars). Error bars represent S.E.M. and ** represents p<0.001, a 2-tailed 
unpaired t-test where all compounds were compared to the wild type control.  
 
After 24 hours, there was a distinct change in the rate of 
development with Cephalomannine and 10-DAB exposed 
worms developing a lot slower compared to those exposed to 
Paclitaxel and the control animals (Figure 3A). This pattern 
continued after 36 hours (Figure 3B) and after 48 hours, over 
80% of control animals were laying eggs, compared to 30% of 
Cephalomannine tested animals (Figure 3C). Around 60% of 
animals exposed to Paclitaxel and 10-DAB were laying eggs 
at 48 hours (Figure 3C). Moreover, 10-DAB potency showed 
some loss of potency between 24 and 48 hours, as over 90% 
of 10-DAB exposed worms were in L1-L3 larval stage after 
24 hours, opposed to less than 30% of control animals. 
 
Figure 3: Developmental fitness of N2 worms on Paclitaxel. Graph 
indicating the percentage of worms in each developmental stage at (A) 24 
hours, (B) 36 hours and (C) 48 hours at 22oC (hours 12 and 60 not shown). 
Developmental speed of animals exposed to paclitaxel is similar to control 
animals. While 10-DAB exposed worms are initially slow in development, 
they catch up to control animals after 48 hours. At all-time points, animals 
exposed to Cephalomannine have significant developmental delay. n=24. 
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Figure 4: Seam cell count results from strains exposed to Taxol derivatives. (A) Wild type L4 larvae (strain JR667), with a control showing an average of 
16 seam cells per side. There is a significant reduction in seam cell counts in the Cephalomannine exposed animals. (B) rnt-1 mutant L4 larvae (strain, AW187), 
with a control showing 11 seam cells per side. There is a significant increase in seam cell number following exposure to all paclitaxel derivatives. (C) rnt-1/bro-
1 overexpressing L4 larvae (strain AW257) with a control showing 27 seam cells per side. Animals exposed to the paclitaxel and Cephalomannine derivatives 
show significantly reduced seam cell number. Each circle represents one worm and for each condition 50 worms were counted. Red circles are control DMSO 
vehicle exposed animals, green circles are 100µg/ml Paclitaxel, blue circles represent 50µg/ml Cephalomannine and purple circles are 250µg/ml 10-DAB. The 
2-tailed unpaired t-test was used, where * p<0.05 and **p<0.01. 
 
The variability in the stem cell-like seam cell number in an 
isogenic C. elegans individual within a population was 
assessed to investigate the effects of the Taxol derivatives on 
stem cells. A wild type, (strain JR667), a rnt-1 mutant (strain 
AW187) and a bro-1 rnt-1 over-expressing (AW257, the cancer 
model) strain were used. In all cases, the parents were exposed 
to either a negative control (DMSO) or Taxol derivatives, and 
the seam cells in the offspring (L4-stage larvae) counted. 
Animals tested under control conditions showed an average of 
16 seam cells per side, as expected (Figure 4A). In contrast, 
worms exposed to Taxol derivatives show a small but 
significant decrease in seam cell number (p<0.01) averaging 
15 seam cells per side in Paclitaxel and Cephalomannine 
exposed worms.  
 
rnt-1 mutant animals (Figure 4B) showed an average of 11 
seam cells per side, as expected. Exposure to the Taxol 
derivatives resulted in a significant increase in seam cell 
number (p<0.001), with an average of 13 and 12 in Paclitaxel 
and Cephalomannine respectively, and an average of 14 seam 
cells in 10-DAB exposed worms. The C. elegans RUNX 
cancer model where rnt-1 and bro-1 are overexpressed, 
resulted in animals having an average of 27 seam cells per side 
(ranging between 21-40) and a tumorous appearance (Figure 
4C). Exposure to 10-DAB did not affect the seam cell number. 
In contrast, Paclitaxel and Cephalomannine exposed bro-1 
rnt-1 overexpressing worms displayed an overall reduction  
 
 
 
 
in seam cell number (p<0.05) with an average of 25 seam 
cells, ranging between 20-34 and 20-32 respectively. 
Discussion 
Extraction of Paclitaxel is costly, inefficient and limited as it 
is derived from the bark of the Taxus plant, a non-sustainable 
source. Recently, there has been investigation towards 
synthetic synthesis of Paclitaxel and to identify renewable 
sources of (the metabolites of) Paclitaxel. The metabolites 
Cephalomannine and 10-DAB are found in the needles and 
twigs of the Taxus plant10, and are a likely sustainable source, 
but their potency and effectiveness as a cancer treatment has 
yet to be fully elucidated. Here we demonstrate the use of C. 
elegans as a platform for the evaluation of Taxol derivatives, 
specifically showing a nuanced potency between Paclitaxel 
and its derivatives. The use of C. elegans in such tests 
highlights how an invertebrate can be used in place of 
vertebrates in cancer studies as well as other testing studies18. 
 
In all our assays, we establish Cephalomannine as a potent 
derivative of Paclitaxel since it exerts similar effects but at 
much lower concentrations. 10-DAB however, is less potent 
compared to Paclitaxel. The differences in potency can be 
explained by their chemical structure, as Cephalomannine has 
a conformational change of the phenyl ring-bearing side chain 
as well as a structural compartmentalization of the bottom side 
chain (Figure 5). Moreover, 10-DAB shows an exclusion of 
two of the phenyl ring-bearing side chains and acetoxy 
moieties, effectively forming only half the structure of 
Paclitaxel (Figure 5).  
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Figure 5. Chemical structure of (A) Paclitaxel, (B) Cephalomannine and 
(C) 10-DAB. (A) Paclitaxel structure includes a dipertene core, 3 phenyl 
bearing side chains and 2 acetoxy moieties. (B) Cephalomannine structure 
shows a conformation change of one phenyl ring-bearing side chain and a 
compartmentalisation of the bottom side chain, when compared to Paclitaxel. 
(C) 10-DAB structure shows the exclusion of the 2 top phenyl ring-bearing 
side chains, when compared to Paclitaxel. Figures were all derived from 
Pubchem sources. 
 
The developmental rate of animals exposed to Paclitaxel and 
10-DAB was not significantly affected, while in contrast, 
Cephalomannine exposure resulted in striking developmental 
delay. Interestingly, while 10-DAB showed an initial delay in 
development during the first 24 hours, this was not the case 
after 48 hours, suggesting 10-DAB is more susceptible to 
degradation or metabolic conversion. Studies show Paclitaxel 
is predominantly metabolized by cytochrome P450s, and it is 
possible that 10-DAB is metabolized to a greater extent than 
Paclitaxel, possibly due to its chemical structure19. 
 
We used C. elegans to observe the effects of Paclitaxel, as the 
solo homolog rnt-1 is the target of Paclitaxel in the same way 
as in mammalian RUNX cancers. In a wild type background, 
all three compounds significantly reduced seam cell number, 
suggesting that the Taxol derivatives are affecting the post-
embryonic seam cell divisions. Strikingly, as C. elegans is 
eutelic (the developmental patterning is highly stereotypical) 
and as the complete lineage of all cells is known, a slight 
change in seam cell number from 16 can be of significant 
interest. In a wild type animal, “extreme” seam cell numbers 
(a 10% deviation from 16 i.e. less than 15 or greater than 17 
seam cells) are very rare20. Indeed, as all strains show more 
than 20% variation in seam cell number, confirming that the 
effects seen were indeed due to Taxol derivative exposure. 
 
While the specific changes to the seam cell division were not 
investigated here, it is likely that the reduction in seam cell 
number is a result of failure to maintain the seam cell 
(proliferative) fate or a failure in execution of the seam cell 
divisions21,22. It is known that rnt-1 is crucial in licensing the 
seam cells to divide6,23, and as Paclitaxel is known to inhibit 
RUNX shuttling7, it is likely that these compounds are 
inhibiting RNT-1 localisation to the nucleus of the 
proliferative daughter in the nematode seam cells. The 
nematode cancer model, with over-expression of rnt-1 and 
bro-1 displays seam cell hyperproliferation, and this is 
reduced following the exposure to Paclitaxel and 
Cephalomannine. However, it is not yet clear how this 
reduction is achieved, and exploring the reasons behind this is 
extremely challenging and beyond the scope of this project.  
 
 
Conclusion 
The object of this study was to evaluate Paclitaxel and its 
derivatives as an effective treatment for RUNX cancer using 
a C. elegans platform. We have shown that the fertility and 
development of C. elegans is affected by Taxol derivatives, 
but we also observed a significant reduction in the number of 
stem cell-like seam cells. In addition, we have shown 
differences in the potency of the 3 compounds extracted from 
the Taxus plants. Together, we demonstrate a basis for testing 
anti-cancer drugs using C. elegans. The advantage of C. 
elegans over a cancer stem cell line, is that it is possible to link 
perturbations of molecular and cellular events to a whole-body 
adverse outcome, such as development or fertility. Finally, we 
suggest that Cephalomannine, extracted from the twigs and 
needles of the Taxus plant, is a potential drug for the treatment 
of RUNX cancers that can be obtained in a sustainable and 
cost-effective manner. C. elegans is an effective and simple 
model system for DART testing17, thus screening the potency 
and toxicity of Cephalomannine and 10-DAB from 
sustainable sources as a potential RUNX cancer treatment will 
contribute to the reduction in the use of vertebrates in cancer 
studies. Indeed, by using this C. elegans cancer model it will 
be possible to explore the molecular interactions of Paclitaxel 
and its derivative’s in a system that is not hampered by genetic 
redundancy13 and form the basis of more informed, targeted 
(cancer) cell culture assays.  
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